Sugi Predict

Sugi Predict / Compounds / SCHEMBL3480152

SCHEMBL3480152

SCHEMBL3480152

O=C(NCc1ccc(S(=O)(=O)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)s1)c1ccc(Cl)cc1

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 1/20 0.63
▸ MAPK10 P53779 1/20 0.63
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ BCL2 P10415 1/20 0.46
▸ BCL2L1 Q07817 1/20 0.46
▸ NPY2R P49146 1/20 0.44
▸ USP5 P45974 2/20 0.44
▸ ALDH1A1 P00352 7/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ EPHX2 P34913 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6454158 0.93 MEN1 (0.66) MAPK9MAPK10MEN1KMT2ANPY2R
SCHEMBL4968910 0.86 MAPK9 (0.52) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL2424773 0.85 MAPK9 (0.63) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL2422442 0.85 MAPK9 (0.65) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL2423811 0.85 MEN1 (0.68) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL2426655 0.85 MAPK9 (0.66) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL1518791 0.84 MAPK9 (0.64) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL2422935 0.84 MAPK9 (0.63) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL6437014 0.83 MAPK9 (0.65) MAPK9MAPK10MEN1KMT2ABCL2
SCHEMBL2419970 0.83 MAPK9 (0.65) MAPK9MAPK10MEN1KMT2ABCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 — — US claimed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 — — US claimed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 — — EP claimed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 — — EP claimed
US-8658640-B2 JNK inhibitors for the treatment of endometriosis MERCK SERONO SA (CH) 2014-02-25 — — US disclosed
US-8592414-B2 JNK inhibitors for the treatment of endometriosis Merck Serono, S.A. (CH) 2013-11-26 — — US disclosed
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-24 — — US disclosed
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-10 — — US disclosed
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 — — US disclosed
US-20090176761-A1 JNK Inhivitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2009-07-09 — — US disclosed
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases LABORATOIRES SERONO SA (CH) 2009-07-09 — — US disclosed
US-20080039377-A1 Composition Comprising a Jnk Inhibitor and Cyclosporin APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2008-02-14 — — US disclosed
EP-1850846-A1 COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN Laboratoires Serono SA (CH) 2007-11-07 — — EP disclosed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 — — US disclosed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 — — EP disclosed
WO-2005097116-A1 COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-10-20 — — WO disclosed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases MAPKAPK2, JUN, MAP3K13 MAPK9 33/4885MAPK10 35/4885MEN1 4590/4885
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes CBR3, INSR, CS MAPK9 2768/4885MAPK10 1940/4885MEN1 3205/4885
US-20080039377-A1 Composition Comprising a Jnk Inhibitor and Cyclosporin LCK, MAPKAPK2, MAP3K20 MAPK9 36/4885MAPK10 40/4885MEN1 1582/4885
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885
US-20090176761-A1 JNK Inhivitors for the Treatment of Endometriosis MAPKAPK2, MAP3K20, MAP3K6 MAPK9 35/4885MAPK10 26/4885MEN1 4390/4885
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.